Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETNA neoadjuvant nab-paclitaxel versus paclitaxel in HER2-negative high-risk breast cancer
2012-003481-41Phase 3Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Jan 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Abraxane arm with Paclitaxel arm (2 arms). Primary endpoint: Pathological complete response. Started Jan 2013; status: terminated.
02
Drugs
nab-paclitaxelpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003481-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003481-41.